six main PROs: body pain, patient global and fatigue score on a 0-10 visual analogue scale, as well as a functional impact score, self-report joint count and symptom checklist. While having a range of 0-10, 0-48 and 0-60 respectively. Composite indices consisting of either two or three of patient pain score 6, self-report joint count 16 and symptom checklist 16 or three of four of the same measures plus a fatigue score have been described previously to provide clues to comorbid FM in other rheumatic diseases [3,4]. Individual PROs and these composite indices were compared between patients with and without FM by student’s t-test and Area Under the Curve (AUC) analysis. The physician’s diagnosis of FM was analysed against the FM criteria using Cohen’s kappa. Physicians were blinded to the results of the 2016 FM criteria. 

Results: 88 patients with SLE were studied, of whom 23 (26%) satisfied FM criteria. Those with FM reported higher scores in all PROs. A patient global of 6 could correctly classify 90% of patients and provided the highest AUC of 0.95, followed by the symptom checklist and body pain. An index of three measures (pain score, self-report joint count and symptom checklist) gave an AUC of 0.90. An index of four measures (additional fatigue criterion) gave an AUC of 0.93. Both indices correctly classified 89% of patients with a cut-off of 2 and 3 respectively. The physician’s diagnoses had moderate agreement with the FM criteria (kappa = 0.43).

<table>
<thead>
<tr>
<th>AUC</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Correctly classified</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 PROs [2]</td>
<td>0.90</td>
<td>78%</td>
<td>92%</td>
</tr>
<tr>
<td>4 PROs [3]</td>
<td>0.93</td>
<td>74%</td>
<td>94%</td>
</tr>
<tr>
<td>Patient global</td>
<td>0.95</td>
<td>91%</td>
<td>89%</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Frank Huang; None declared, Sean O’Neill; None declared, Ray Fang; None declared, Matthew Nguyen; None declared, Kathryn Gibson Grant/research support from: UCB, Abbvie, Speakers bureau: UCB, Janssen


THU0267

ULTRASONOGRAPHY IN THE DIAGNOSIS OF LOWER LIMB ENTHESOPATHY IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: RELATION TO THE DISEASE ACTIVITY

Reem A. Habeeb, Maryam A. Abdel Rahman, Dalia Abdel Hamid Elsherbiny, Safaa A. Hussein, Heba A. Mustafa. Internal Medicine Department, Division of Rheumatology, Ain Shams University, Cairo, Egypt.

Background: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease characterized by variable clinical manifestations due to different organ involvement1. Musculoskeletal involvement is extremely common in patients with SLE. Musculoskeletal ultrasound (MSUS) is an important tool for evaluation of patients with inflammatory arthritis and early detection of subclinical inflammation at the joint, tendon and entheseal level2. 

Objectives: To investigate the presence of entheseal abnormalities in SLE patients and correlating it with parameters of disease activity.

Methods: In this cross-sectional study we evaluated 50 patients with SLE who fulfilled the 2012 ACR/SLICC criteria3. Patients underwent clinical laboratory and ultrasonographic examination of both lower limbs at the sites of entheses. Disease activity was assessed by using the SLE disease activity index (SLEDAI)4. The scanned entheses were those included in the Glasgow Ultrasound Enthesitis Scoring System (GUESS)5. The anatomical sites were scanned bilaterally, both in longitudinal and transverse planes, in grey-scale (GS) and power Doppler (PD) mode. Ultrasonography was performed using (esaote) MyLab6Six ultrasound machine, equipped with a 6-18 MHz linear probe.

Results: In our cohort of SLE patients we found 29 patients had clearly evident MSUS features of enthesopathy (58%) and 16 patients with minimal and isolated entheseal abnormalities (32%). Five patients had normal MSUS findings with no evidence of entheseal affection (10%). The mean of total GUESS score of all patients was 3.54 ± 2.6. MSUS examination of the quadriceps tendon insertion at the patella revealed mean thickness of 5.89 ± 0.7 mm, the patellar tendon attachment at the patella (proximal) was 4.26 ± 0.84 mm and the mean thickness of the patellar tendon at the tibial insertion (distal) was 4.08 ± 0.7 mm. The Achilles tendon insertion at the superior pole of calcaneus and the plantar fascia insertion at inferior pole of calcaneus were 4.2 ± 0.7 and 3.7 ± 0.7 mm respectively. Age, body mass index (BMI), SLEDAI score, and ESR1 had a highly significant positive correlation with GUESS score. The increase in BMI, SLEDAI score and creatinine had an independent effect on increasing GUESS score. 

Conclusion: Lower limb enthesopathy is common in SLE patients and considered one of the important causes of knee and ankle joints pain. Enthesal involvement in SLE patients is affected by variable parameters, mainly disease activity. Enthesal abnormalities can be early detected by ultrasonography even in clinically asymptomatic SLE patients without evidence of clinical symptoms and/or signs of entheseal affection.

REFERENCES:

Disclosure of Interests: None declared


THU0266

THE SLE DISEASE ACTIVITY SCORE (SLE-DAS) ENABLES ACCURATE DEFINITIONS OF SLE REMISSION AND LDA AS ACHIEVABLE TARGETS IN DISEASE MANAGEMENT

Diogo Jesus1,2, Ana Matos3,4, Carla Henriques3,5, Margherita Zeni6, Maddalena Larosa6, Luca Iaccarino6, Andrea Doria6, Luis Inês1,2.

1Centro Hospitalar e Universitário de Coimbra, Rheumatology Department, Coimbra, Portugal. 2University of Beira Interior, Faculty of Health Sciences, Covilhã, Portugal. 3Polytechnic Institute of Viseu, School of Technology and Management, Viseu, Portugal. 4Polytechnic Institute of Viseu, Center for Research in Digital Services, Viseu, Portugal. 5University of Coimbra, Centre for Mathematics, Coimbra, Portugal. 6University of Padova, Division of Rheumatology, Padova, Italy.

Background: The treat-to-target strategy in Systemic Lupus Erythematosus (SLE) aims to achieve remission. However, to define a target based on the C Disease Activity Index (SLEDAI) is questionable, due to its limitations (especially its dichotomous nature). The SLE Disease Activity Score (SLE-DAS) is a recently validated continuous disease activity score which has a higher accuracy in measuring SLE activity and a higher sensitivity-to-change compared to SLEDAI.

Objectives: To assess the ability of SLE-DAS to define SLE remission and other disease activity states.

Methods: Cross-sectional study of SLE patients fulfilling the ACR97 and/or SLICC12 classification criteria and followed at the Padua Lupus Clinic from March to June 2018. At each outpatient visit, the attending clinician scored SLE disease activity in the last 30 days) using Physician Global